Semax and Selank: The Nootropic Research Blend Explained

What Semax and Selank Is

Semax and Selank is a research blend that pairs two synthetic peptides which are frequently investigated side by side in the nootropic and neuroscience literature. Rather than a single molecule, the blend brings together two short, proline-rich peptides that were each developed as regulatory peptide analogues and that have overlapping but complementary profiles in preclinical study.

Semax is a heptapeptide analogue based on a fragment of adrenocorticotropic hormone, specifically the ACTH 4-10 region, extended with a proline-glycine-proline tail that improves its stability. It is investigated largely as a neuroprotective and cognition-associated research compound. Selank is a heptapeptide analogue of the endogenous immunopeptide tuftsin, and it is studied predominantly in the context of anxiety-like behaviour, stress physiology and neuroimmune signalling.

The two are grouped together because researchers designing cognitive or stress paradigms often want to observe an attention-and-signalling axis alongside a stress-and-resilience axis in the same investigation. NovaPeptides supplies the blend strictly as a laboratory reagent for that kind of work, with no human use intended.

The Two Components, Explained Separately

Understanding the blend means understanding each peptide on its own. They are structurally distinct, come from different parent molecules, and are associated with different primary research areas, even though their downstream effects overlap in interesting ways.

Semax

• Structure: a heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH 4-10 sequence with a stabilising Pro-Gly-Pro extension.
• Origin: developed in Russia as a regulatory peptide analogue, where it has a long history in the neuroscience research literature.
• Research framing: most often examined as a neuroprotective and cognition-associated compound, including in ischaemia and neurotrophic-signalling models.
• Notable feature: unlike its ACTH parent, Semax is studied as non-corticotropic, meaning the research literature associates it with neural rather than classic hormonal-adrenal signalling.

Selank

• Structure: a heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, an analogue of the endogenous tetrapeptide tuftsin.
• Origin: also developed in Russia, designed to extend the short half-life of natural tuftsin while retaining its regulatory activity.
• Research framing: studied primarily around anxiety-like behaviour, stress responses and neuroimmune modulation.
• Notable feature: as a tuftsin analogue, Selank appears in the literature alongside immunomodulatory and cytokine-related research, not just behavioural work.

Mechanism and Receptor Targets in the Research Literature

Neither peptide acts on a single classical receptor in the way a small-molecule drug might. Instead, the published research describes both as regulatory peptides that modulate several interconnected signalling systems. The following is a summary of mechanisms named in the scientific literature, described as research observations rather than as effects promised to any person.

Mechanisms associated with Semax

• Modulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB, along with nerve growth factor (NGF) signalling.
• Influence on the dopaminergic, serotonergic and cholinergic systems in study models.
• Regulation of the activity of enkephalin-degrading enzymes, which is thought to prolong endogenous regulatory peptide signalling.
• Broad effects on gene expression, with hippocampal transcription studies reporting changes across many genes involved in neural signalling and neuroprotection.

Mechanisms associated with Selank

• Modulation of BDNF expression, an area of overlap with Semax that partly explains why the two are studied together.
• Interaction with the GABAergic system, which is central to its investigation in anxiety-model research.
• Effects on the balance of monoamines and on enkephalin-degrading enzyme activity.
• Immunomodulatory and cytokine-related activity, consistent with its origin as a tuftsin analogue, including reported influence on interleukin expression.

What the Blend Is Studied For

The research areas below describe what investigators have examined in cells, animal models and, in the case of the original Russian literature, some clinical study populations. They are stated here as research directions only. Nothing in this section is a claim that the blend does any of these things in a person, and NovaPeptides makes no therapeutic or performance promise.

• Attention, focus and working memory paradigms, where Semax in particular is a frequent subject.
• Stress-resilience and anxiety-like behaviour models, where Selank is the more studied component.
• Neuroprotection research, including ischaemia and oxidative-stress models.
• Neuroinflammation and neuroimmune signalling, drawing on Selank's tuftsin lineage.
• Neurotrophic and neuroplasticity signalling, centred on BDNF, NGF and downstream pathways.
• Combined cognition-and-stress designs, where the blend lets a single model observe both axes at once.

The value of studying Semax and Selank together is not that one is better than the other. It is that they let a research model observe a focus-and-signalling axis and a stress-and-resilience axis in parallel, using two well-characterised regulatory peptides.

The Research Landscape

Both peptides have an unusually long research history for compounds of this class, much of it originating in Russian neuroscience institutes from the late twentieth century onward. That literature spans mechanistic biochemistry, gene expression work, animal behavioural models and, for the individual peptides, some clinical study populations described in region-specific publications.

For a researcher, the practical reading of that landscape is twofold. First, there is a substantial mechanistic base describing how each peptide interacts with neurotrophic, monoaminergic and neuroimmune systems, which makes them useful reference reagents. Second, much of the human-facing literature sits outside the frameworks and regulatory approvals that Australian and Western clinical practice relies on, which is exactly why these materials are handled as research compounds and not as medicines here.

How the Blend Is Handled in a Laboratory Context

This section describes how peptide reagents of this kind are generally handled in a research setting so the material remains stable and its identity intact. It is background information for laboratory work, not instructions for human use, and NovaPeptides provides no dosing, protocol or administration guidance of any kind.

• Lyophilised peptide blends are typically supplied as a dry powder and are kept cold and dry until a study calls for reconstitution.
• Reconstitution, concentration and any handling parameters are defined by the qualified researcher running the study, in line with their own institutional protocols.
• Short proline-rich peptides such as these are valued in research partly for their relative stability, but they still degrade with heat, light and repeated freeze-thaw cycles, so cold-chain and storage discipline matter.
• Every reconstitution and measurement should be traceable back to the batch and its Certificate of Analysis, so results can be tied to verified material.
• All handling is for in vitro or defined research use only, by people qualified to work with laboratory reagents.

Sourcing and Verification

With research peptides, two things determine whether a result is trustworthy: the identity of the material and its purity. A blend is only useful as a reagent if you can confirm that what is in the vial matches the label, which is why independent testing sits at the centre of how NovaPeptides supplies this product.

Every batch is paired with an independent Novagen Laboratories Certificate of Analysis that carries a unique verification key. That key lets the certificate be matched to the specific batch received, so identity and purity can be checked against documented analysis rather than simply taken on trust. Reading the COA before any research work should be a routine first step.

What verification lets a researcher confirm

• That the material corresponds to the labelled Semax and Selank blend.
• That the batch has documented purity from an independent laboratory.
• That the certificate on file matches the exact batch in hand, via its unique key.
• That results can be traced back to verified starting material if the work is ever reviewed or repeated.

Why Researchers Source This From NovaPeptides

NovaPeptides is an Australian owned supplier based on the Gold Coast that has supplied research peptides to Australians for over three years. That track record matters in a category where consistency, traceability and reliable dispatch are what separate a usable research reagent from an unknown quantity.

What comes with every order

• An independent Novagen Laboratories Certificate of Analysis with a unique key on every batch, so identity and purity can be verified.
• Australian owned and Gold Coast based supply, with over three years of serving Australian researchers.
• Same day Gold Coast dispatch with discreet, tracked delivery across Australia.
• A consistent research-use-only framing, with no human use claims and no dosing guidance.

Research Use Status

This is the part that governs everything else on this page. Semax and Selank is a research compound. It is not TGA approved for human use, it is not a registered medicine, and it is supplied strictly for laboratory and research use only.

• Not approved by the Therapeutic Goods Administration for human consumption.
• Not intended to diagnose, treat, cure or prevent any condition.
• Supplied for laboratory and research use only, to be handled by qualified researchers.
• No dosing, human-use or administration guidance is provided, and none of the research observations described above are promises to any reader.

Frequently asked questions

Related guides